Biocon Biologics has entered a definitive agreement with Eris Lifesciences to divest its Dermatology and Nephrology branded formulations business units in India for INR 3,660 million, allowing both companies to focus on their core strategic goals.

Information on the Target

Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited, has made significant strides as a fully integrated global biosimilars company. Focused on transforming healthcare accessibility, BBL is dedicated to providing high-quality biosimilars for patients worldwide. The recent divestiture of its Dermatology and Nephrology branded formulations business units in India aligns with its strategic goal of concentrating on core therapy areas such as Diabetes, Oncology, and Immunology.

The Dermatology and Nephrology units, essential parts of BBL's legacy small molecules' portfolio, encompass a range of established products and significant expertise within these therapeutic areas. With over 120 employees expected to transition to Eris Lifesciences as part of this 'Slump Sale' transaction, BBL aims to ensure a smooth handover of responsibilities and continuity of care for patients currently relying on these treatments.

Industry Overview in India

India's pharmaceutical industry has experienced robust growth, driven by a rising demand for affordable and accessible healthcare. Characterized as one of the largest in the world, the Indian pharmaceutical market has been known for its produc